Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study

ConclusionsThe rates of SAEs in both groups were low. The IVB and IVR treatments were not associated with significant risks of mortality, ATE, and non-fatal HF.Trial RegistrationThai Clinical Trial Registry identifier TCTR20141002001.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research